Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Massage Reduces Fluid Volume in Lymphoedema Patients but Does Not Improve Arm Function: Presented at ASTRO - (DGDispatch)
    Patients With Centrally Located and Progesterone-Negative Tumours May Need More Aggressive Treatment Following Breast-Conserving Surgery: Presented at ASTRO - (DGDispatch)
    TopAbstracts in Breast Cancer 11/03/2009 - (DGNews)
    Early-Stage, HER2-Positive Breast Cancer Patients at Increased Risk of Recurrence - (DGNews)
    TopAbstracts in Breast Cancer 10/27/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer
    Cutaneous Metastasis of Breast Carcinoma Presenting as Alopecia Neoplastica

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Breast Pseudotumoral Radionecrosis as a Late Radiation-Induced Injury: A Case Report
      Large Family with Both Parents Affected by Distinct BRCA1 Mutations: Implications for Genetic Testing
      Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer
      Ruptured Gallbladder as the First Presentation of Breast Cancer
      Synchronous Infiltrating Ductal Carcinoma and Primary Extramedullary Plasmacytoma of the Breast

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Docetaxel Improves Survival in Women With Metastatic Breast Cancer: Presented at SABCS

      By Charlene Laino

      SAN ANTONIO, TX -- December 4, 2003 -- For women with metastatic breast cancer who have failed prior chemotherapy, docetaxel is associated with a significant improvement in overall survival and time to disease progression, when compared with paclitaxel, a Phase III randomised trial shows.

      Despite an increase in certain toxicities, there was no difference in quality-of-life scores between the 2 groups, said Stephen E. Jones, MD, Medical Director of U.S. Oncology Research and Director of Breast Cancer Research, Baylor-Sammons Cancer Center, Dallas, Texas, United States. Dr. Jones presented the findings here on December 3rd at the 26th annual San Antonio Breast Cancer Symposium.

      The trial -- the first to directly compare docetaxel and paclitaxel -- enrolled 449 women with metastatic breast cancer, who were randomised to receive either 100 mg/m2 of docetaxel as a 1-hour infusion or 175 mg/m2 of paclitaxel as a 3-hour infusion, every 3 weeks. The drugs were continued until progression of disease, unmanageable toxicity, or until the patient opted to terminate treatment.

      In the intent-to-treat population, median survival was 15.4 months in the arm receiving docetaxel, compared with 12.7 months in the group receiving paclitaxel. This finding translated to 41% relative improvement in overall survival attributable to docetaxel, which was significant at the P = .03 level, Dr. Jones reported.

      Also, time to disease progression was 5.7 months for women taking docetaxel, compared with 3.6 months for those on paclitaxel. This translated to a 62% improvement in time to disease progression (P < .0001).

      Overall response rates were 32% in the docetaxel arm versus 25.0% in the paclitaxel arm (P = .10), the study showed.

      There were more haematological toxicities with docetaxel therapy, Dr. Jones said, mainly Grade 3/4 neutropenia. Fifteen percent of the patients in the docetaxel arm suffered febrile neutropenia versus 2% of patients on paclitaxel.

      Quality-of-life scores, however, as assessed by a modified Functional Assessment of Cancer Therapy questionnaire, were not significantly different between the 2 arms after 4 cycles of treatment, Dr. Jones reported.

      Aventis Pharmaceuticals sponsored this trial.


      [Study Title: Randomized Trial Comparing Docetaxel and Paclitaxel in Patients with Metastatic Breast Cancer. Abstract 10]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send